News + Font Resize -

Final FDA nod for Mylan's Fentanyl Transdermal System
Pittsburgh | Wednesday, February 2, 2005, 08:00 Hrs  [IST]

The US Food and Drug Administration has granted final approval for Mylan Technologies' Abbreviated New Drug Application for Fentanyl Transdermal System in 25 mcg/hr, 50 mcg/hr, 75 mcg/hr and 100 mcg/hr strengths. Fentanyl is the generic version of Alza Corporation's Duragesic.

Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories Inc. and Mylan Bertek Pharmaceuticals Inc., that develop, license, manufacture, market and distribute an extensive line of generic and proprietary products.

Post Your Comment

 

Enquiry Form